

From: [Charles Kandziolka](#)
To: [AGO - High Cost Prescription Drugs](#)
Subject: Nubeqa (darolutamide)
Date: Thursday, August 1, 2019 11:36:24 AM

Hello,

Pursuant to 18 V.S.A. § 4637, Bayer is notifying the Vermont Attorney General's Office that the introductory wholesale acquisition cost of Nubeqa (darolutamide) is in excess of the Medicare Part D specialty drug threshold.

Product	NDC	WAC
Nubeqa® (darolutamide) 300 mg tablet	50419-395-01	\$11,550.00

Nubeqa is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

More details about Nubeqa will be provided in the 30-day reporting requirement.

Kind regards,

Charles Kandziolka
Strategic Pricing & Reimbursement

Bayer: Science For A Better Life

Bayer U.S. Market Access
100 Bayer Boulevard, PO Box 915
Building B200, 2B4234
Whippany, NJ 07981-0915, USA
Tel: (862) 404-4802
Mobile: (862) 812-9702
E-mail: charles.kandziolka@bayer.com